Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 6, 2009, Pages 1265-1273

  Chantarangsu, Soranun ^a   Cressey, Tim R ^b,c   Mahasirimongkol, Surakameth ^d   Capparelli, Edmund ^e   Tawon, Yardpiroon ^c   Ngo Giang Huong, Nicole ^b,c   Jourdain, Gonzague ^b,c   Lallemant, Marc ^b,c   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pharmacogenetics; Single nucleotide polymorphisms; SNPs

Indexed keywords

ADENINE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; CYTOSINE; GUANINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; THYMINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; N DEMETHYLASE; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME INDUCTION; FEMALE; GENE MUTATION; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFANT; INTRAPARTUM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; THAILAND; VERTICAL TRANSMISSION; VIRUS RESISTANCE; VIRUS TRANSMISSION; CHEMISTRY; DISEASE TRANSMISSION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; NEWBORN; PLASMA; POLYMERASE CHAIN REACTION; PREGNANCY; TIME;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HAPLOTYPES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; PLASMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; THAILAND; TIME FACTORS; YOUNG ADULT;

EID: 73549117428     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp351     Document Type: Article

References (35)

1. WHO Guidelines. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach. Version 2006. http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html (29 June 2009, date last accessed).
2. Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-28.
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229-40.
4. Lockman S, Shapiro RL, Smeaton LM et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356: 135-47.
5. Cressey TR, Jourdain G, Lallemant MJ et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38: 283-8.
6. Chaix ML, Ekouevi DK, Peytavin G et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother 2007; 51: 896-901.
7. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 2007; 7: 333-42.
8. Erickson DA, Mather G, Trager WF et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-95.
9. Jinno H, Tanaka-Kagawa T, Ohno A et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 2003; 31: 398-403.
10. Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
11. Xie HJ, Yasar U, Lundgren S et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3: 53-61.
12. Rotger M, Colombo S, Furrer H et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
13. Penzak SR, Kabuye G, Mugyenyi P et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8: 86-91.
14. Saitoh A, Sarles E, Capparelli E et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-9.
15. Chantarangsu S, Cressey T, Mahasirimongkol S et al. Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G.T polymorphism. Mol Cell Probes 2007; 21: 408-11.
16. Fellay J, Marzolini C, Meaden ER et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-6.
17. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
18. Holland DT, DiFrancesco R, Stone J et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004; 48: 824-31.
19. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guide. University of California, San Francisco: NONMEM Project Group; 1994.
20. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887-93.
21. Shibata K, Ito T, Kitamura Y et al. Simultaneous estimation of haplotype frequencies and quantitative trait parameters: applications to the test of association between phenotype and diplotype configuration. Genetics 2004; 168: 525-39.
22. Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, 2007.www.R-project.org (29 June 2009, date last accessed).
23. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61: 914-8.
24. Xu BY, Guo LP, Lee SS et al. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. World J Gastroenterol 2007; 13: 2100-3.
25. Mahungu T, Smith C, Turner F et al. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200mg twice daily and 400mg once daily in an ethnically diverse population. HIV Med 2009; 10: 310-7.
26. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071-87.
27. Boehringer-Ingelheim Pharmaceuticals Ltd. Viramune® (nevirapine) tablets and oral suspension. Prescribing information. 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020636s027,0209 33s017lbl.pdf (29 June 2009, date last accessed).
28. Lamson M, MacGregor T, Riska P et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways. In: Abstracts of the One hundredth Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Antonio, TX, 1999. Abstract PI-79. Clin Pharmacol Ther 1999; 65: 137.
29. Haas DW, Gebretsadik T, Mayo G et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199: 872-80.
30. Brumme ZL, Dong WW, Chan KJ et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003; 17: 201-8.
31. Haas DW, Smeaton LM, Shafer RW et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192: 1931-42.
32. Stormer E, von Moltke LL, Perloff MD et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19: 1038-45.
33. Owen A, Almond L, Hartkoorn R et al. Relevance of drug transporters and drug metabolism enzymes to nevirapine: superimposition of host genotype. In: Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Abstract 650. http://www.retroconference.org/2005/cd/Abstracts/24878.htm (29 June 2009, date last accessed).
34. Lamba J, Lamba V, Strom S et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169-81.
35. Siccardi M, D'Avolio A, Baietto L et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47: 1222-5.